Previous 10 | Next 10 |
home / stock / ipcif / ipcif news
2023-07-17 10:55:47 ET Intellipharmaceutics International press release ( OTC:IPCIF ): Q2 GAAP EPS of $0.00. Revenue of $480.21M. For further details see: Intellipharmaceutics International GAAP EPS of $0.00, revenue of $480.21M
TORONTO, ON / ACCESSWIRE / July 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release...
2023-06-06 06:24:37 ET Intellipharmaceutics International press release ( OTC:IPCIF ): FY GAAP EPS of -$0.09. Revenue of $0.06M. For First Quarter 2023: The Company recorded GAAP EPS of -$0.01/common share. The company recorded revenues of $0.33M for the three mont...
Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results Canada NewsWire TORONTO , June 6, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical c...
Intellipharmaceutics Announces Cease Trade Order Canada NewsWire TORONTO , March 7, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the...
Intellipharmaceutics Provides Update on Management Cease Trade Order Application and Anticipates Cease Trade Order Canada NewsWire TORONTO , Feb. 7, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) (" Intellipharmaceutics " or t...
Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application Canada NewsWire TORONTO , Feb. 6, 2023 /CNW/ - Intellipharmaceutics International Inc. (OT...
TORONTO, ON / ACCESSWIRE / October 14, 2022 / - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-r...
Intellipharmaceutics International ( OTC:IPCIF ) on Tuesday said it had inked a Canadian license and supply agreement with Taro Pharmaceuticals ( NYSE: TARO ) for depression treatment desvenlafaxine. Shares of OTC-listed IPCIF closed 18.6% higher at $0.10 on Monday whi...
TORONTO, ON / ACCESSWIRE / August 16, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rele...
News, Short Squeeze, Breakout and More Instantly...
Intellipharmaceutics International Inc Company Name:
IPCIF Stock Symbol:
OTCMKTS Market:
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel...
TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-re...
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release...